Specifically, miR-150 promotes NSCLC growth via SIRT2/JMJD2A activation, while miR-206 suppresses hepatocellular carcinoma by targeting c-MET (27, 29). This evidence concerns the gene SIRT2 and non-small cell lung carcinoma.